

# Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

NCT05724446

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Salvat
Enrollment	60 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Male or female, aged 0 to 3 years old (have not had their 4th birthday) on the day of consent.
- Patients who are candidate for routine, uncomplicated cataract surgery in one eye with or without intraocular lens.
- Patients whose caregiver(s) is/are able and willing to comply with all treatment and follow-up procedures.
- Signed informed consent from (ICF) parents or patient's legally authorized representative(s).
- Patients who have undergone routine, uncomplicated cataract surgery in one eye with or without intraocular lens.

... and 1 more (see full listing online)

### Exclusion (19)

- Presence of any active or suspected viral, bacterial, or fungal disease in the study eye.
- Active uveitis in the study eye.
- Ocular neoplasia in the study eye.
- Post-traumatic cataract in the study eye.
- Suspected permanent low vision or blindness in the fellow non-study eye. The study eye must not be the patient's only good eye.

... and 14 more (see full listing online)

## Locations (1 total)

---

Hospital Sant Joan de Deu, Barcelona, Spain